Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Inventory (2016 - 2025)

Protalix BioTherapeutics has reported Inventory over the past 16 years, most recently at $25.7 million for Q4 2025.

  • Quarterly results put Inventory at $25.7 million for Q4 2025, up 21.12% from a year ago — trailing twelve months through Dec 2025 was $25.7 million (up 21.12% YoY), and the annual figure for FY2025 was $25.7 million, up 21.12%.
  • Inventory for Q4 2025 was $25.7 million at Protalix BioTherapeutics, up from $21.3 million in the prior quarter.
  • Over the last five years, Inventory for PLX hit a ceiling of $25.7 million in Q4 2025 and a floor of $13.6 million in Q2 2021.
  • Median Inventory over the past 5 years was $19.3 million (2023), compared with a mean of $18.7 million.
  • Biggest five-year swings in Inventory: soared 48.21% in 2023 and later fell 20.31% in 2024.
  • Protalix BioTherapeutics' Inventory stood at $18.0 million in 2021, then decreased by 6.41% to $16.8 million in 2022, then grew by 13.34% to $19.0 million in 2023, then grew by 11.54% to $21.2 million in 2024, then grew by 21.12% to $25.7 million in 2025.
  • The last three reported values for Inventory were $25.7 million (Q4 2025), $21.3 million (Q3 2025), and $21.1 million (Q2 2025) per Business Quant data.